-
BTIG Sets $12 Price Target On Rockwell Medical, Sees 63% Upside
Friday, August 19, 2016 - 12:13pm | 324Read More...BTIG has started coverage on Rockwell Medical Inc (NASDAQ: RMTI) with a Buy and a price target of $12, saying that its lead asset, Triferic, has the potential to replace IV iron in hemodialysis patients. Triferic is indicated to replace iron and maintain hemoglobin in hemodialysis patients versus...
-
Rockwell Medical Is Getting Killed Because Of These Numbers
Tuesday, March 1, 2016 - 10:31am | 257Read More...Shares of Rockwell Medical Inc (NASDAQ: RMTI) were trading lower by more than 35 percent ahead of Tuesday's market open. Rockwell Medical said that it lost $0.12 per share in the fourth quarter on revenue of $14.1 million – short of the $0.02 per share Wall Street analysts expected the...
-
Why Shares Of Rockwell Medical Are Up Huge
Monday, January 26, 2015 - 11:01am | 257Read More...Shares of Rockwell Medical Inc (NASDAQ: RMTI) were trading higher by more than percent after the company announced the FDA has approved its Triferic (ferric pyrophosphate solution) intended for the maintenance of hemoglobin in adult patients with hemodialysis dependent chronic kidney disease....
-
What Investors Should Expect From Rockwell Medical's Next FDA Decision
Wednesday, January 7, 2015 - 5:22pm | 359Read More...On Wednesday, Rockwell Medical Inc (NASDAQ: RMTI) announced it will be presenting two Triferic abstracts at the Annual Dialysis Conference on February 2 in New Orleans. Triferic is the company's iron-replacement drug used for iron deficiency in chronic kidney disease patients receiving...
